SETD2 and lung adenocarcinoma: The majority of SETD2 mutations identified in lung adenocarcinoma are truncating mutations that result in the production of truncated proteins lacking either the histone methyltransferase Su(var)3-9, Enhancer-of-zeste and Trithorax (SET) domain or the Set2-Rpb1–interacting (SRI) domain that mediates the interaction of SETD2 with Pol II.